Intravenous MSC infusion is outpatient, requiring 30–60 minutes for administration. Mild fever, fatigue, or localised discomfort may occur 24–48 hours post-infusion; paracetamol and rest are usually sufficient. Intra-muscular or intrathecal injection requires brief specialised anaesthesia and observation for 2–4 hours; same-day discharge is standard. No prolonged immobility or surgical recovery is needed. Patients resume normal activities within 24–48 hours. Concomitant physiotherapy and neuropathy management (foot care, glycaemic control) continue uninterrupted; downtime is negligible.
Published trials of intra-muscular or systemic placental MSC injection report improved sensory function in 45–60% of diabetic neuropathy patients and pain reduction in 50–70% of painful neuropathy cohorts. Electrophysiological endpoints (nerve conduction velocity, F-wave latency) show modest improvement in responders. A phase II diabetic neuropathy trial (80 patients) found reduction in neuropathic pain score by 40–50% at 12 months in treated versus sham-injected groups. Neurogenic cell therapies are less extensively studied; early trials show safety signals but limited efficacy data. Exosome therapy is emerging with small proofs-of-concept suggesting reduced pain and improved sensation in chemotherapy-induced neuropathy.
Am I a candidate? → · Peripheral Neuropathy: full overview → · Peripheral Neuropathy cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
GMP-сертифицированная регенеративная медицина в сердце ЕС — от €3 000–8 000, доля от цен США или Германии. Индивидуальные протоколы для пациентов из 50+ стран.
Бесплатная оценка врача